T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.
- Mechanism
- Curator reviewed
T-5224 is an inhibitor of the transcription factor AP-1 (Activator Protein-1) which is known to play an important role in the pathology of rheumatoid arthritis. AP-1 turns on a variety of genes in response to inflammation triggers, including many that are responsible for the proteins that are the targets of current rheumatoid arthritis products. In addition, in joint cells called osteoclasts, AP-1 stimulates the production of enzymes that are thought specifically to cause the destruction of bones and joint tissue. Therefore, by inhibiting the AP-1 process, T-5224 affects several key pathways and may prevent the progression of this disabling disease in many patients.
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Formula / weight
- C29H27NO8 · 517.534 g/mol (avg)
- Code names
- 3-(5-(4-(CYCLOPENTOXY)-2-HYDROXY-BENZOYL)-2-((3-HYDROXY-1,2-BENZOXAZOL-6-YL)METHOXY)PHENYL)PROPANOIC ACID · BENZENEPROPANOIC ACID, 5-(4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL)-2-((2,3-DIHYDRO-3-OXO-1,2-BENZISOXAZOL-6-YL)METHOXY)- · R-7277 · T5224
Resolves to
DALCQQSLNPLQFZ-UHFFFAOYSA-NSMILESOC(=O)CCC1=CC(=CC=C1OCC1=CC2=C(C=C1)C(O)=NO2)C(=O)C1=C(O)C=C(OC2CCCC2)C=C1What you can answer from here — as of March 06, 2025
Which drugs share a target with T-5224, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account